- Home
- BOLT vs SLGL Comparison
BOLT vs SLGL Comparison
Compare BOLT & SLGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BOLT
- SLGL
- Stock Information
- Founded
- BOLT 2015
- SLGL 1997
- Country
- BOLT United States
- SLGL Israel
- Employees
- BOLT N/A
- SLGL N/A
- Industry
- BOLT Biotechnology: Pharmaceutical Preparations
- SLGL Biotechnology: Pharmaceutical Preparations
- Sector
- BOLT Health Care
- SLGL Health Care
- Exchange
- BOLT Nasdaq
- SLGL Nasdaq
- Market Cap
- BOLT 16.8M
- SLGL 19.3M
- IPO Year
- BOLT 2021
- SLGL 2018
- Fundamental
- Price
- BOLT $5.65
- SLGL $7.62
- Analyst Decision
- BOLT Buy
- SLGL Buy
- Analyst Count
- BOLT 3
- SLGL 1
- Target Price
- BOLT $50.00
- SLGL $40.00
- AVG Volume (30 Days)
- BOLT 20.2K
- SLGL 6.5K
- Earning Date
- BOLT 08-12-2025
- SLGL 08-15-2025
- Dividend Yield
- BOLT N/A
- SLGL N/A
- EPS Growth
- BOLT N/A
- SLGL N/A
- EPS
- BOLT N/A
- SLGL N/A
- Revenue
- BOLT $3,638,000.00
- SLGL $12,103,000.00
- Revenue This Year
- BOLT N/A
- SLGL N/A
- Revenue Next Year
- BOLT $24.14
- SLGL $31.17
- P/E Ratio
- BOLT N/A
- SLGL N/A
- Revenue Growth
- BOLT N/A
- SLGL 603.66
- 52 Week Low
- BOLT $5.20
- SLGL $3.34
- 52 Week High
- BOLT $15.60
- SLGL $16.50
- Technical
- Relative Strength Index (RSI)
- BOLT 47.50
- SLGL 68.44
- Support Level
- BOLT $5.68
- SLGL $6.96
- Resistance Level
- BOLT $6.40
- SLGL $7.48
- Average True Range (ATR)
- BOLT 0.27
- SLGL 0.25
- MACD
- BOLT 0.07
- SLGL 0.11
- Stochastic Oscillator
- BOLT 50.00
- SLGL 100.00
About BOLT Bolt Biotherapeutics Inc.
Bolt Biotherapeutics Inc is a clinical-stage immuno-oncology company. It is developing tumor-targeted therapies that leverage the power of the innate and adaptive immune systems. The company's pipeline candidates are built on our deep expertise in myeloid biology and cancer drug development. The company's proprietary Boltbody ISAC platform technology combines tumor-targeting antibodies with immune-stimulating linker-payloads. The company's pipeline consists of BDC-1001, BDC-3042, and Next-Gen ISAC.
About SLGL Sol-Gel Technologies Ltd.
Sol-Gel Technologies Ltd is a dermatology company. It is engaged in identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases. The company's product candidate pipeline includes SGT-610 (Patidegib Gel 2%), a new chemical entity hedgehog signaling pathway blocker, for the chronic use and prevention of new BCC in Gorlin syndrome patients, and the topical drug candidate SGT-210 for the treatment of Darier Disease and other rare keratosis-related indications such as PC, PPK and Olmsted.